Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Sep 6, 2026, 16:41Christina (Tina) P.: APS – How it Happens in Your Blood, the Warning Signs, and What to Do about It
-
Sep 6, 2026, 16:33Jose Angel Nicolas Avila: How Tissue Mitochondrial Activity Dictates Macrophage Pool Size
-
Sep 6, 2026, 16:23Kevin Buda: Many High-Risk PE Patients Have Contraindications to Thrombolysis
-
Sep 6, 2026, 16:16Venk Murthy: 2018 vs 2026 ACC/AHA Lipid Guidelines – A Shift From RCTs to Expert Opinion?
-
Sep 6, 2026, 16:11Silmara Montalvão: Improving Global Hemophilia Diagnostics Through Sustained External Quality Assessment
-
Sep 6, 2026, 14:50Mohamed F Doheim: Unraveling the Symphony of Stroke Management
-
Sep 6, 2026, 14:47Ahmed Bennis: E-Cigarette Use and Early Cardiovascular Risk in Young Adults
-
Sep 6, 2026, 14:46William Wallace: Iron Deficiency Can be Present Before Hemoglobin Falls and Before Anemia Appears
-
Sep 6, 2026, 14:15Listening to One Another Drives Innovation and Better Therapies in Hemophilia Care – Global Hemophilia Report